Flex Pharma Inc(NASDAQ:FLKS) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during Pre-market on Aug 3, 2016. Earnings per share were $-0.71. Analysts had estimated an EPS of $-0.67.
Flex Pharma Inc (FLKS) made into the market gainers list on Fridays trading session with the shares advancing 1.63% or 0.18 points. Due to strong positive momentum, the stock ended at $11.25, which is also near the day’s high of $11.3711. The stock began the session at $11.1 and the volume stood at 37,853 shares. The 52-week high of the shares is $16.9763 and the 52 week low is $6.48. The company has a current market capitalization of $202 M and it has 1,79,68,475 shares in outstanding.
Several Insider Transactions has been reported to the SEC. On Jul 12, 2016, John Sculley (director) purchased 4,709 shares at $11.60 per share price.Also, On Jun 24, 2016, Christoph H Westphal (CEO) purchased 2,700 shares at $11.28 per share price.On Mar 16, 2016, Michelle Stacy (director) purchased 2,585 shares at $9.63 per share price, according to the Form-4 filing with the securities and exchange commission.
Flex Pharma Inc. is a biotechnology company that is developing treatments for exercise-associated muscle cramps nocturnal leg cramps and spasms for neuromuscular conditions. The Company focuses its drug development efforts on developing a product to treat nocturnal leg cramps. The Company’s treatment which forms the basis of both drug product and consumer product development efforts activates the transient receptor potential (TRP) cation channel receptors in primary sensory neurons in the spinal cord that enhances overall inhibitory tone in motor neurons throughout the body. The Company’s pre-clinical drug product candidates are offered for Nocturnal leg cramps and MS spasticity cervical dystonia and/or SCI spasticity. The Company’s consumer brand and products focuses athletes experiencing exercise-associated muscle cramps or EAMCs. The Company has commenced formulation and commercialization efforts of its consumer brand.